Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Citius Pharmaceuticals Inc (CTXR) vs NRG Energy Inc (NRG) Price & Performance

Citius Pharmaceuticals IncTrade
NRG Energy IncTrade

Price performance (Past 24H)

Key statistics

Citius Pharmaceuticals Inc vs NRG Energy Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.72 (market cap $20.01M), while NRG Energy Inc trades at $120.63 (market cap $24.83B). The key difference: NRG Energy Inc is far larger — about 1240.9× Citius Pharmaceuticals Inc's market cap, and NRG Energy Inc pays a 1.61% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

CTXRNRG
Market Cap
$20.01M$24.83B
Sector
HealthUtilities
52-Week High
$1.82$184.03
52-Week Low
$0.48$117.04
Enterprise Value
$16.23M$48.79B
Dividend Yield
1.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Citius Pharmaceuticals Inc

CTXR is trading at $0.7126, up 5.26% today, with strong technical momentum showing bullish moving average signals. The company shows significant revenue growth potential with LYMPHIR commercialization expanding, though currently operates at substantial losses with a -823% net income margin. Analyst sentiment remains overwhelmingly positive with 83% buy ratings, reflecting optimism about the oncology pipeline and recent commercial progress.

The investment case hinges on successful LYMPHIR commercialization offsetting current losses, with strong institutional support providing runway. Key risks include execution challenges in scaling operations and the capital-intensive nature of biopharmaceutical development. The stock presents high-risk, high-reward potential for investors comfortable with clinical-stage biotech volatility.

NRG Energy Inc

NRG Energy trades at $120.97, up 1.73% today, with a bearish technical signal despite oversold RSI levels near support at $119. The company reported Q2 2026 EPS of $1.49, missing estimates of $1.69, but revenue grew 11% year-over-year, driven by cost controls and a strategic 1.2 GW Texas data-center power project. Fundamentals show a P/E of 30.76 and ROE of 26.77%, though net margin is thin at 2.56%.

Outlook is mixed: analyst consensus is bullish with a $207.83 price target (69% buy ratings), citing growth from data-center demand, but risks include rising interest costs, high leverage (debt-to-assets at 56.42% in 2025), and earnings misses. The stock offers a 1.6% dividend yield, but investors face volatility from execution risks in expansion plans.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Citius Pharmaceuticals Inc

Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.

Read more on CTXR

About NRG Energy Inc

NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.

Read more on NRG